Dr. Christopher Lelliott, PhD
Chris Lelliott Wellcome Trust Sanger Institute
I received my PhD in Clinical Biochemistry from Cambridge University under supervision of Toni Vidal-Puig in 2003 studying proteins involved in lipodystrophies and the Metabolic Syndrome. I subsequently became a post-doctoral fellow at AstraZeneca, Sweden in 2004 studying the control of metabolic processes by PGC1 transcription coactivators in vitro and in vivo. In 2006, I became an Associate Principle Scientist within the Cardiovascular & Gastrointestinal Area, where I was responsible for generation and assessment of new projects and lead optimisation programs within Insulin Resistance, Type 2 Diabetes and Obesity, using my extensive experience of mouse metabolic phenotyping and viral technologies combined with pharmacological assays.
I joined the Mouse Genetics Project at WTSI in 2012, where I am Senior Scientific Manager for In Life Phenotyping. My team is responsible for phenotyping and analysing data from mouse lines that are generated within the MGP. I am also establishing a secondary phenotyping program to perform further characterisation of novel and interesting mouse lines, including those that display metabolic and physiological abnormalities.